Citigroup’s China Biologic Products Holdings, Inc. CBPO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-95,847
| Closed | -$11.3M | – | 6632 |
|
|
2021
Q1 | $11.3M | Buy |
95,847
+32,514
| +51% | +$3.85M | 0.01% | 1297 |
|
|
2020
Q4 | $7.48M | Buy |
63,333
+56,265
| +796% | +$6.53M | ﹤0.01% | 1795 |
|
|
2020
Q3 | $786K | Buy |
7,068
+4,497
| +175% | +$483K | ﹤0.01% | 3489 |
|
|
2020
Q2 | $263K | Sell |
2,571
-1,422
| -36% | -$152K | ﹤0.01% | 4809 |
|
|
2020
Q1 | $431K | Sell |
3,993
-5,980
| -60% | -$687K | ﹤0.01% | 4012 |
|
|
2019
Q4 | $1.16M | Sell |
9,973
-20,027
| -67% | -$2.32M | ﹤0.01% | 3610 |
|
|
2019
Q3 | $3.43M | Hold |
30,000
| – | – | ﹤0.01% | 2290 |
|
|
2019
Q2 | $2.86M | Buy |
30,000
+29,253
| +3,916% | +$2.75M | ﹤0.01% | 2458 |
|
|
2019
Q1 | $68K | Sell |
747
-8,647
| -92% | -$708K | ﹤0.01% | 6094 |
|
|
2018
Q4 | $714K | Sell |
9,394
-13,199
| -58% | -$971K | ﹤0.01% | 3744 |
|
|
2018
Q3 | $1.81M | Sell |
22,593
-3,609
| -14% | -$336K | ﹤0.01% | 2845 |
|
|
2018
Q2 | $2.6M | Buy |
26,202
+26,080
| +21,377% | +$2.25M | ﹤0.01% | 2452 |
|
|
2018
Q1 | $10K | Sell |
122
-749
| -86% | -$60.5K | ﹤0.01% | 7070 |
|
|
2017
Q4 | $69K | Buy |
+871
| New | +$72.4K | ﹤0.01% | 5953 |
|
|
2017
Q3 | – | Sell |
-11,748
| Closed | -$1.33M | – | 7671 |
|
|
2017
Q2 | $1.33M | Buy |
11,748
+4,378
| +59% | +$489K | ﹤0.01% | 3012 |
|
|
2017
Q1 | $738K | Sell |
7,370
-140
| -2% | -$15K | ﹤0.01% | 3527 |
|
|
2016
Q4 | $807K | Buy |
7,510
+1,552
| +26% | +$181K | ﹤0.01% | 3911 |
|
|
2016
Q3 | $742K | Buy |
5,958
+273
| +5% | +$32.2K | ﹤0.01% | 3531 |
|
|
2016
Q2 | $604K | Sell |
5,685
-3,274
| -37% | -$380K | ﹤0.01% | 3457 |
|
|
2016
Q1 | $1.02M | Sell |
8,959
-21
| -0.2% | -$2.46K | ﹤0.01% | 3309 |
|
|
2015
Q4 | $1.28M | Buy |
8,980
+7,996
| +813% | +$923K | ﹤0.01% | 2863 |
|
|
2015
Q3 | $88K | Sell |
984
-672
| -41% | -$70.9K | ﹤0.01% | 5064 |
|
|
2015
Q2 | $191K | Sell |
1,656
-970
| -37% | -$102K | ﹤0.01% | 4479 |
|
|
2015
Q1 | $251K | Buy |
2,626
+692
| +36% | +$51.8K | ﹤0.01% | 4320 |
|
|
2014
Q4 | $130K | Buy |
1,934
+746
| +63% | +$46.2K | ﹤0.01% | 5032 |
|
|
2014
Q3 | $64K | Buy |
1,188
+1,182
| +19,700% | +$58.2K | ﹤0.01% | 5122 |
|
|
2014
Q2 | $0 | Sell |
6
-19
| -76% | -$776 | ﹤0.01% | 7469 |
|
|
2014
Q1 | $1K | Sell |
25
-52
| -68% | -$1.66K | ﹤0.01% | 6922 |
|
|
2013
Q4 | $2K | Buy |
+77
| New | +$2.23K | ﹤0.01% | 6813 |
|
|
2013
Q3 | – | Sell |
-72
| Closed | -$2K | – | 7129 |
|
|
2013
Q2 | $2K | Buy |
+72
| New | +$1.82K | ﹤0.01% | 6560 |
|
Citigroup's CBPO Position: Q2 2021 in Review
Citigroup sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 95,847 shares — an estimated $11.3M sold.
Citigroup first reported a position in CBPO in Q2 2013 and held it in 30 quarters. The position peaked at $11.3M in Q1 2021. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.
- Citigroup reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
- Citigroup sold 95,847 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $11.3M.
- Citigroup first reported a position in China Biologic Products Holdings, Inc. in Q2 2013 and held it in 30 quarters.
- Citigroup's China Biologic Products Holdings, Inc. position peaked at $11.3M in Q1 2021.
- 0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.
Based on Citigroup's 13F filing for Q2 2021, filed 10 Aug 2021.